ClinicalTrials.gg
CompletedNCT00109395Updated Mar 20, 2023

Lorazepam Sedation for Critically Ill Children

A Phase 2/3 interventional study of Lorazepam and Midazolam in Critical Illness, sponsored by The Emmes Company, LLC. Completed at 1 site in United States. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2023-03-20.

Sponsored by The Emmes Company, LLC · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
179
Allocation
Randomized
Ages
1 Day to 18 Years
Sex
All
01

Study summary

This clinical trial is being performed under the Best Pharmaceuticals for Children Act, signed into law in 2002 in order to improve pediatric labeling for off-patent drugs. The purpose of this study is to make sure that lorazepam, when given to children who are very sick in the Intensive Care Unit and who are on a breathing machine, is safe and works as well as a drug called midazolam. Midazolam is already approved by the FDA for this use, but lorazepam is not, even though both drugs are commonly used for sedation.

Read the detailed description

Lorazepam is used clinically for sedation of mechanically ventilated children, but has not been approved by the FDA for this indication in children. The purpose of this study, in response to the Written Request by FDA, is to determine the safety, efficacy, and dosage required for lorazepam compared with midazolam, which is approved by FDA for children for this indication.

Study participants must be children who are critically ill and receiving mechanical ventilation who require sedation. Participants will be randomized to lorazepam (intermittent bolus or continuous infusion) or midazolam (continuous infusion). Sedation will be monitored using the COMFORT score. Blood will be drawn to measure lorazepam/midazolam plasma concentrations, and to measure the plasma concentrations of excipients (benzyl alcohol and glycols) in patients receiving lorazepam.

02

Conditions studied

  • Critical Illness

Browse trials for

Keywords

  • Lorazepam
  • Midazolam
  • Best Pharmaceuticals for Children Act
  • Critically ill
  • pediatrics
  • mechanical ventilation
  • sedation
03

In context

Critical Illness

1,782 studies on the registry are indexed under Critical Illness; 443 are open to participants now.

This study's enrollment of 179 is above the median of 90 across 928 interventional studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

The Emmes Company, LLC is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females from full term birth (at least 38 weeks post conceptual age) through 18 years
  • Patients must be intubated and mechanically ventilated in the PICU less than or equal to 24 hr
  • Patients in whom the use of neuromuscular blocking agents would normally NOT be expected to be used.
  • Patient's parent or guardian has signed a consent form prior to initiation of study procedures
  • Patients with cardiac, renal, or hepatic dysfunction will be actively sought

Exclusion criteria

Exclusion Criteria:

  • \< 48 hr
  • Expected duration of sedation \< 48 hr
  • Patient with history of to any component of lorazepam, midazolam, fentanyl, thiopental
  • Females pregnant or breast feeding
  • Patient requires sedatives or analgesics other than study drug
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
179 participants (actual)

Study arms

  • Active comparator
    Lorazepam Intermittent bolus

    lorazepam administered by intermittent bolus

    Drug: Lorazepam

  • Active comparator
    lorazepam continuous infusion

    lorazepam administered by continuous infusion

    Drug: Lorazepam CI

  • Active comparator
    midazolam continous infusion

    midazolam administered by continous infusion

    Drug: Midazolam

Interventions

  • Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score

    Also known as: Ativan

  • Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score

    Also known as: Versed

  • Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score

    Also known as: Ativan

06

What researchers measure

Primary outcomes

  1. Rate of Severe Adverse Events

    Duration of study participation

    Time frame: Minimum 8 hours

  2. Number of bolus doses required to achieve a comfort score of 17 ≤ 26

    A measurement of drug efficacy

    Time frame: minimum of 8 hours

  3. Drug dose required to maintain a target comfort score of 17 ≤ 26

    Measurement of efficacy

    Time frame: Minimum of 8 hours

07

Study locations

1 site
  • Case Western Reserve University
    Cleveland, Ohio 44106-6010, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2005
First posted
Apr 28, 2005
Start
Sep 2004
Primary completionActual
Sep 2007
CompletionActual
Sep 2007
Last update
Mar 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00109395
Lead sponsor
The Emmes Company, LLC
Responsible party
Sponsor
First posted
Apr 28, 2005
Start date
Sep 2004
Primary completion
Sep 2007
Completion
Sep 2007
Last update
Mar 20, 2023

Study contacts

Jeffrey L Blumer, MD, PhD
principal investigator · Case Western Reserve University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lorazepam · Midazolam

Start the discussion